Chronic liver inflammation (chronic hepatitis B, fatty hepatitis)
Conditions
Interventions
Gold Standard:Liver biopsy was performed to evaluate liver inflammation according to the GS scoring system, the Metavir scoring system and the Ishak scoring system.
Sponsors
Beijing Friendship Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Retrospective 1. Age 18 years or older, any gender; 2. Patients with a history of liver biopsy-confirmed chronic liver inflammation (chronic hepatitis B, steatohepatitis), and for whom liver biopsy specimens or pathology images/reports are available; 3. Patients who underwent iLivTouch examination within +/-7 days of the liver biopsy, with results that can be exported; 4. Patients for whom demographic, biochemical, and etiological information within 7 days before and after the liver biopsy is available. Prospective: 1. Age 18 years or older, any gender; 2. Clinically diagnosed with chronic hepatitis and agree to undergo liver biopsy and concurrent iLivTouch examination (interval <+/-7 days); 3. Voluntarily sign a written informed consent form.
Exclusion criteria
Exclusion criteria: Retrospective: 1. Combined with other chronic liver diseases (drug-induced liver injury, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease, etc., excluding fatty liver); 2. Use of drugs within one month that may directly affect liver function test indicators (such as bicyclol, polyene phosphatidylcholine, Schisandra-containing traditional Chinese medicine, silymarin, glycyrrhizin, etc.); 3. Patients with more than 50% missing demographic, biochemical, or etiological information. Prospective: 1. Patients with hepatic conditions involving significant deposition of abnormal substances other than fat and collagen, such as obstructive bile duct disease, cholestatic liver disease, and inherited metabolic liver diseases; 2. Patients who have taken medications within the past month that may directly affect liver function test indicators (such as bifendate, Wuzi capsule, traditional Chinese medicine containing Schisandra, silymarin compounds, glycyrrhizin derivatives, polyunsaturated phosphatidylcholine, etc.); 3. Patients with unresolved wounds or scars in the right upper abdomen that make ultrasound examination inappropriate; 4. Any contraindications to liver puncture, including but not limited to: (1) clinical consideration of hepatic hemangioma or multilocular echinococcosis; (2) extrahepatic obstructive jaundice; (3) significant bleeding tendency, or severe thrombocytopenia or coagulation disorders; (4) coma or uncooperative due to other diseases; (5) infection along the puncture path. 5. Any contraindications to iLivTouch, including but not limited to active infection in the right upper abdomen, pregnancy, etc.; 6. Patients with severe diseases of major organs such as the heart, lungs, kidneys, brain, or hematologic system; 7. Patients with severe mental illnesses (such as depression, mania, schizophrenia, etc.); 8. Pregnant and breastfeeding women; 9. Patients deemed by the investigators as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specificity;Clinical diagnostic threshold; | — |
Countries
China
Contacts
Public ContactWu Xiaoning
Beijing Friendship Hospital Affiliated to Capital Medical University
Outcome results
None listed